Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina·2020·Diabetes, Obesity and Metabolism

DOI 10.1111/dom.13955

Cited by (208)

Items 101–200 of 208

Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
Bykova Aa, Maria Serova, M. I. Chashkina, Raisa S. Kosharnaia, Z. K. Salpagarova, Denis A. Andreev, Ilya Giverts · 2024 · Cardiac failure review
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Celestine I. Odigwe, Rajasekhar R. Mulyala, Haijra Malik, Brent Ruiz, Mariam Riad, Mohammad As Sayiadeh, Sanchitha Honganur, Alexis Parks, Mustafeez Ur Rahman, Nasser M. Lakkis · 2025 · American Heart Journal Plus Cardiology Research and Practice
Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
Rui Wu, Bo Xing, Yuting Huang, Zijun Zhou, Boxuan Sun, Liming Yu, Huishan Wang · 2025 · Frontiers in Endocrinology
GLP ‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial
Masashi Hasebe, Chen‐Yang Su, Hisashi Kamido, Daisuke Yabe, Satoshi Yoshiji · 2026 · Diabetes Obesity and Metabolism
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review
Areti Sofogianni, Κωνσταντίνος Τζιόμαλος · 2020 · Advances in Therapy
A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure
Ushna Gul, Thandar Aung, Mehwish Martin, Daanyal Noor Farrukh, P. Shah, Zeenia S Lovely, Esaúl Marroquín León, Mohamed Alansaari, Shriya Maini, Muddasir Mohammed Fariduddin et al. · 2024 · Cureus
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Anna Pendrey, Javier Sevilla‐Martir · 2025 · Obesity
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
Subodh Verma, Udi Fainberg, Mansoor Husain, Søren Rasmussen, Lars Rydén, Maria Sejersten Ripa, John B. Buse · 2021 · Diabetes Obesity and Metabolism
Notable Underlying Mechanism for Pancreatic β-Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Junpei Sanada, Yoshiro Fushimi, Naoto Katakami, Taka‐aki Matsuoka, Kohei Kaku · 2020 · International Journal of Molecular Sciences
Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6
Jingmin Zhou, Mansoor Husain, Yang Li, Wenyan Liu, Zewei Shen, Tina Vilsbøll, Junbo Ge · 2025 · Diabetes Obesity and Metabolism
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Muhammad Shahzeb Khan, Muhammad Hamza Dawood, Yehuda Handelsman, Stefan D. Anker, Andrew J.S. Coats, Jennifer B. Green, Javed Butler · 2026 · European Heart Journal
factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme
Crabtree, Tom, Adamson, Karen, Bickerton, Alex, Evans, Alison, Phillips, Suzanne, Gallagher, Alison, Larsen, Niels, Barnes, Dennis, Dhatariya, Ketan, Field, Benjamin CT et al. · 2023 · British Journal of Diabetes
Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Aaron King, Xi Tan, Neil Dhopeshwarkar, Rhonda L. Bohn, Katherine Dea, Charles E. Leonard, Adam de Havenon · 2025 · American Journal of Preventive Cardiology
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Timothy D. Roberts, Dana S. Hutchinson, Denise L. Wootten, Miles J. De Blasio, Rebecca Helen Ritchie · 2025 · Journal of Molecular and Cellular Cardiology
Oral Semaglutide: Dosage in Special Situations
Sanjay Kalra, Nitin Kapoor · 2022 · Diabetes Therapy
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions
Jingjing Zhu, John P.H. Wilding, Xiaosong Gu · 2024 · World Journal of Diabetes
Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes
Jillian Fetzner, Ebne Rafi · 2025 · The Journal of Clinical Endocrinology & Metabolism
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Rashmi Thapa, Kyla M. Lara-Breitinger, Francisco Alejandro López-Jiménez, Nishat Shama, Alexander C. Egbe, William R. Miranda, Heidi M. Connolly, Christopher Charles Jain, Maan Jokhadar, Angela M. Kosec et al. · 2025 · JACC Advances
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Niki Katsiki, Kyriakos Kazakos, Filippos K. Triposkiadis · 2022 · Expert Opinion on Pharmacotherapy
Oral semaglutide: the innovation in type 2 diabetes management
Marina Vladimirovna Shestakova, Минара Шамхаловна Шамхалова, Gagik Radikovich Galstyan, Lyudmila Alexandrovna Ruyatkina, Л. А. Суплотова · 2021 · Diabetes Mellitus
GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice
Lola A. Coke, PRAKASH C. DEEDWANIA, Debbie Hinnen, Melissa Magwire, Nancy Houston Miller · 2022 · Journal of the American Association of Nurse Practitioners
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
Katherine Young, Eram Haider McInnes, Robert J. Massey, Anna R Kahkohska, Scott J. Pilla, Sridharan Raghavan, Maggie A. Stanislawski, Deirdre Kay Tobias, Andrew Peter McGovern, Adem Y. Dawed et al. · 2023 · medRxiv
Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges
Wenling Fu, Roujun Lu, Dongdong Wang, Zhipei Sang · 2026 · Bioorganic Chemistry
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
James J. Amamoo, Riddhi Doshi, Joshua Noone, Lin Ying Xie, Cory L. Gamble, Mico Guevarra, Victoria M. Divino, Justin Chen, Aaron King · 2025 · Diabetes Therapy
Cardiovascular complications in Diabetes: The role of NLRP3 inflammasome and targeted interventions
Gnanaprakash Jeyaraj · 2025 · Obesity Medicine
Safety and Efficacy of Semaglutide Use in Diabetes during Ramadan Fasting: A Real-world Experience from Bangladesh
Md Faruque Pathan, Nazma Akter, Shahjada Selim, Md Feroz Amin, Faria Afsana, Mohammad Saifuddin, Abul B. M. Kamrul-Hasan, Marufa Mustari, Ashish Kumar Chakraborty, Riad Mohammad Moshaed Hossain · 2024 · Bangladesh Journal of Endocrinology and Metabolism
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study
Binayak Sinha, Samit Ghosal · 2024 · Diabetes Therapy
Exploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications
Rui Miguel Pinheiro Vitorino · 2024 · European Journal of Clinical Investigation
Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide)
Luca Antonio Felice Di Odoardo, Ottavio Zucchetti, Edoardo Sciatti, Salvatore D’Isa, Emilia D’Elia, Michele Senni · 2025 · European Heart Journal Supplements
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Leonardo De Luca, Claudio Bilato, Alessandro Navazio, Marco Corda, Massimo Milli, Pietro Scicchitano, Massimo Di Marco, Carmine Riccio, Giovanna Geraci, Attilio Iacovoni et al. · 2025 · European Heart Journal Supplements
Novel approaches to pharmacological management of type 2 diabetes in Japan
Shizuka Kaneko · 2021 · Expert Opinion on Pharmacotherapy
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Ali Alromaih, Abdullah Alshamrani, Bandar Alharbi, Ibtissam Alharbi, Turki Alharbi, Samia Bokhari, Hussein Elbadawi, Mohammed S. Almehthel, Abdulghani Habib Alsaeed, Khalid Alyahia et al. · 2023 · Journal of Diabetes Mellitus
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes
Maxwell Salvatore, Bingyu Zhang, Huilin Tang, Yiwen Lu, Dazheng Zhang, Ting Zhou, Yuan Lu, Anastassia Amaro, Marylyn DeRiggi Ritchie, Yong Chen · 2025 · medRxiv
First-in-Class Oral Semaglutide
Rajesh Rajput, Sujoy Ghosh, Samar Banerjee, Beena Bansal, Manoj S Chawla, Abhay I Ahluwalia, Tejal Bipin Lathia, Ashok K. Das · 2022 · Indian Journal of Endocrinology and Metabolism
Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines
Zhanna D. Kobalava, Е. В. Кохан · 2020 · Kardiologiia
Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
Carlos Mario Balcázar Valencia, Andrés Felipe García Ramos, Luis Miguel Osorio-Toro, Yessica Alejandra Ordoñez-Guzman, Nathalia Buitrago Gómez, William López, Carlos Vizcaino-Guerrero, Jorge Enrique Daza-Arana, Alex Ramírez Rincón, Katherine Restrepo-Erazo · 2024 · Diabetes Metabolic Syndrome and Obesity
Treatment of Type 2 Diabetes in Patients with Obesity
Heidi Guzman, Leen Z. Hasan, Tirissa J. Reid · 2024 · Endocrinology and Metabolism Clinics of North America
Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p
Basel A. Abdel‐Wahab, Ehab A. M. El‐Shoura, Mohammed Shafiuddin Habeeb, Nayef Abdulaziz Aldabaan, Yasmine H. Ahmed, Dalia K. Zaafar · 2024 · Steroids
Treatment of Obesity in Heart Failure
Biykem Bozkurt · 2024 · JACC Heart Failure
Adiposity-based Chronic Diseases and the Therapeutic Role of Glucagon-like Peptide-1 Receptor Agonists
RAJIV R. KOVIL, Tejas Shah, Snehal Tanna, Vijay B Negalur, SONALI A. PATANGE, Ami Sanghvi, PC Manoria, MANGESH HARIHAR TIWASKAR, DAKSHATA A. PADHYE, Alpana Sowani et al. · 2025 · International Journal of Diabetes and Technology
Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study
Alessandra Piccione, Maria Bonsangue, Martina Barone, Enrica Vigneri, Mariagrazia Irene Mineo, Laura Tomasello, Laura Maniscalco, Felicia Pantò, Giorgio Arnaldi, Valentina Guarnotta · 2025 · Nutrition Metabolism and Cardiovascular Diseases
GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1–40 in diabetes
Ignatios Ikonomidis, Anastasios Papageorgiou, George Pavlidis, Georgios A. Georgiopoulos, Konstantinos Katogiannis, Eirini Maratou, John Thymis, Loukia Pliouta, Aikaterini Kountouri, Emmanouil Korakas et al. · 2026 · American Journal of Physiology-Heart and Circulatory Physiology
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes
Brij Teli, Shrikant Somani, Vivek Arya, Prashant J Rajput, Pravin Kahale, Vahid S. Bharmal, Shalin Shah, Vivek Patel, Anand Ahuja, SONALI A. PATANGE · 2026 · Cureus
Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD )
Óscar Moreno, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez, Virginia Soria-Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez-Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan José Gorgojo Martínez et al. · 2026 · Diabetes Obesity and Metabolism
Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6
Miles Fisher · 2021 · British Journal of Diabetes
Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials
Shota Obata, Yoshihisa Miyamoto, Leandro N. Slipczuk, Hisato Takagi, Toshiki Kuno · 2022 · Journal of Cardiovascular Medicine
A glükagonszerűpeptid-1-receptor-agonisták cardio- és neuroprotectiv szerepe a 2-es típusú diabetest kísérő ischaemiás stroke előfordulásának mérséklésében
Gábor Winkler, András Folyovich, János Tibor Kis, Tamara Dancs, László Schandl · 2024 · Orvosi Hetilap
Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients
Nishtha Gupta, Tesingin D Uwawah, Kamaldeep Singh, Hritik Madan, Siddharth Kumar, Bharat Midha, Kriti Soni, Aparjit Singh, Amandeep Bhogal, Arpit Jain · 2024 · Cureus
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Andrijana Kirsch, Juergen Gindlhuber, Diana Zabini, Elena Osto · 2025 · Frontiers in Cardiovascular Medicine
Evaluation of Clinical and Quality of Life Effects of Oral Semaglutide Use in Type 2 Diabetes from a Public Health View: A Prospective Study in Italy
Paola Pantanetti, Vanessa Ronconi, Stefano Mancin, Cristina De Carolis, Sara Alberti, Orietta Pazzi, Sandra Di Marco, Grazia Michetti, Silvia Coacci, V.E. Mignini et al. · 2025 · Diabetology
GLP1-receptor-agonisták: antidiabetikumok kardiovaszkuláris előnnyel
György Jermendy · 2020 · Cardiologia Hungarica
Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Nathan D. Wong · 2022 · Canadian Journal of Physiology and Pharmacology
ІНСУЛІНОРЕЗИСТЕНТНІСТЬ ТА ГІПЕРГЛІКЕМІЯ – ОСНОВНІ ПРЕДИКТОРИ УСКЛАДНЕНОГО ПЕРЕБІГУ ГОСТРОГО ІНФАРКТУ МІОКАРДА У ХВОРИХ ІЗ КОМОРБІДНИМ МЕТАБОЛІЧНИМ СИНДРОМОМ ТА ЦУКРОВИМ ДІАБЕТОМ 2-ГО ТИПУ
М. І. Швед, I.O. Yastremska, Р. М. Овсійчук · 2023 · Здобутки клінічної і експериментальної медицини
Diagnostic significance of cardiac bridging integrator 1 score in hospitalized patients with heart failure with preserved ejection fraction and its assessment of prognostic value for major adverse cardiac events
Xia Guo, Haoxuan Chu, Hanchi Xu, Zhen Yi Guo, Yulin Tian, Shipeng Wang, Yushi Wang · 2025 · BMC Cardiovascular Disorders
Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis
Xincheng Li, Gejing Liu, Yongming Liu · 2025 · Precision medication.
Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT)
Fernando Stuardo Wyss, Vladimir E. Ullauri, Joffre J. Lara-Terán, Andrés Arteaga-Arellano, Carolina Gómez Martín, Ricardo López-Santi, Gonzálo Pérez, Carlos Armando Madrigal, Mayra Ger, Daniel Leonardo Piskorz et al. · 2026 · Diabetology & Metabolic Syndrome
Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
Carlos Escobar, Almudena Castro, Jorge Francisco Gómez Cerezo, José Luis Górriz, Juan Carlos Obaya, Rocío Villar‐Taibo · 2022 · Revista Española de Cardiología Suplementos
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
Martina Matovinović, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić, Martina Lovrić Benčić · 2024 · Diabetology
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Richa Kahol, Anjali Jain, Niti Sharma, Sunil Kumar Mishra · 2024 · International Journal of Innovative Science and Research Technology (IJISRT)
The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional study
Peter Shane Hamblin, Arul Earnest, Anthony William Russell, Stella Talic, Ella Zomer, Sophia Zoungas · 2024 · The Lancet Regional Health - Western Pacific
Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis
Muhammad Hamayal, Chaudhary Humayun Akhtar, Naveed Ahmad, Muhammad Awwab, Warda Shahid, Hasan Shaukat Abbasi, Esha Nadeem, Erum Siddiqui, Wadana Zafar, Saima Hussain · 2025 · American Journal of Cardiovascular Drugs
Approaching sleep apnea management in the setting of uncertainty
Lucas M. Donovan, Sanjay R. Patel · 2022 · SLEEP
Alert-LDL-2: adherence to guidelines and goals attainment in the treatment of diabetic patients with dyslipidemia
Mariarosaria De Luca, Giorgio Bosso, Giovanni Alma, Vincenzo Carbone, Ferdinando Ferrara, Biagio Fimiani, Franco Guarnaccia, Alessandro IANDOLO, Sabato Murolo, Maurizio Olivares et al. · 2023 · Minerva Cardiology and Angiology
Lower Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Two Large Italian Cohorts
Marta Baviera, Stefano Genovese, Vito Luigi Lepore, Pierluca Colacioppo, Fabio Robusto, Mauro Tettamanti, Antonio D'Ettorre, Fausto Avanzini, Ida Fortino, Antonio Nicolucci et al. · 2020 · Research Square
GLP-1 receptor agonists: evolution and advancement in the treatment of type 2 diabetes mellitus
Candido, R. · 2021 · The Journal of AMD
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Anjali Agarwalla, Jadry Gruen, Carli J. Peters, Lauren E. Sinnenberg, ANJALI TIKU OWENS, Nosheen Reza · 2022 · Cardiac failure review
Semaglutide: A Strategic Weapon for Primary Care
Akshay Jain · 2022 · The Singapore Family Physician
Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist
E. Soubry, Chantal Mathieu, G. Vandistel, Ann C. Mertens · 2022 · Tijdschrift voor Geneeskunde
Series: Cardiovascular outcome trials for diabetes drugs.
Miles Fisher · 2022 · British Journal of Diabetes
Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control
La Salle J, Kari Uusinarkaus, Family Medicine, CHPG Primary Care, CO, USA, Marso SP, Cardiovascular Medicine, HCA Midwest Health, KS, USA, Kevin M. Pantalone · 2023 · Journal of Family Medicine
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Shurui Hong · 2023 · BIO Web of Conferences
Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death
Gitanjali Srivastava · 2023 · Obesity Pillars
Diabetes and obesity
Rubina Hakeem, Thamina Rashid, Muhammad Adil Sheikh · 2024 · Elsevier eBooks
Oral semaglutide improves glycemic control and lowers blood lipids: evidence from a real-world study
Dora Gašparini, Fabijan Čakanić, Tomislav Tufekčić, Darko Rasnek, Felix M. Wensveen, Tamara Turk Wensveen · 2024 · Cardiovascular Endocrinology & Metabolism
Semaglutide-a ray of hope for CKD in diabetic patients
Usama Khan · 2025 · Journal of the Pakistan Medical Association
The Emerging Trend of Managing Type 2 Diabetes with Oral Semaglutide
Supratik Bhattacharyya · 2025 · Clinical Diabetology
Antihypertensive Wirkungen von SGLT-2-Inhibitoren und GLP-1-Rezeptoragonisten
Walter Zidek · 2025 · Nephrologie aktuell
A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients with Type 2 Diabetes
Michelle Panol Del Rosario, Celeste Ong-Ramos · 2025 · Philippine Journal of Internal Medicine
Additional file 4 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 8 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 1 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 7 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 6 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 5 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 2 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 6 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 7 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 5 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 3 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 4 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 1 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 3 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Additional file 9 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Mansoor Husain, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko · 2020 · Figshare
Additional file 2 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Bain, Stephen C., Heidrun Bosch‐Traberg, Ekaterina Sokareva, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G. · 2023 · Figshare
Hat die inkretinbasierte Hypertoniebehandlung eine Zukunft?
Walter Zidek · 2026 · CardioVasc
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Thomaz Alexandre Costa, Josephine Harrington, Adam J. Nelson, Ambarish Pandey, Ian J. Neeland, Matthew M.Y. Lee, Yu Mi Kang, Darren K. McGuire · 2026 · Current Treatment Options in Cardiovascular Medicine
Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events and worsening heart failure in patients with heart failure: an umbrella meta-analysis
Changxin Sun, Chuchuan Meng, Yongfang Yuan, Lanqing Hu, Xiaoya Li, Min Wu, Longtao Liu · 2026 · BMC Endocrine Disorders
Role of adipose tissue macrophages in Beta 3-adrenergic receptor-mediated beige adipogenesis and thermogenesis
Raoul Manuel · 2024
Impact de la stéatohépatite non alcoolique sur le remodelage myocardique et sur les complications cardiovasculaires
Raphaël Decoin · 2023
Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category
Angelo Navas, JOSHUA NOONE, Nathan Laney, SUNNY T. SHETH, Xi Tan, Yuanjie Michael Liang, Paloma Munoz, Caroline Swift · 2026 · Diabetes Therapy